Although glucocorticoids inhibit inflammation and are used to treat painful inflammatory rheumatic diseases, the contribution, if any, of endogenous pituitary-adrenocortical activity to the control of pain remains unclear. We report that injection of dilute formalin into the hindpaw not only evokes inflammation and pain-related behavior, but it also increases ACTH and corticosterone to a greater extent than restraint and saline injection alone. This difference was particularly robust during the final periods of pain-related behavior in the formalin test, when the ACTH and corticosterone (B) levels in the restraint/saline control group had returned to normal. These results indicate that formalin-evoked increases in ACTH and B reflect nociceptive input, rather than the stress associated with handling. To test the hypothesis that the formalin-induced increase in corticosterone reduces pain and inflammation, we next evaluated the effect of adrenalectomy (to prevent activation of glucocorticoid receptors) or high-dose dexamethasone (to saturate glucocorticoid receptors) on nociceptive processing in the formalin test. Neither adrenalectomy nor dexamethasone changed behavioral or cardiovascular nociceptive responses. Furthermore, the increases in blood pressure and heart rate produced by formalin may not be mediated by adrenomedullary catecholamine release. In addition, we conclude that the nociceptive component of the formalin stimulus is sufficient to activate the pituitary-adrenocortical system in the awake rat, but that the resulting release of corticosterone does not feed back and reduce nociceptive processing. (Endocrinology 139: [2407][2408][2409][2410][2411][2412][2413] 1998) T ISSUE injury and an accompanying inflammation are associated with persistent stimulation of primary afferent C-fibers, which transmit nociceptive messages from the periphery to the dorsal horn of the spinal cord. This process can be facilitated by both an injury-induced release of proinflammatory peptides from nerve terminals in the periphery and by a noxious stimulus-induced sensitization of dorsal horn neurons in the spinal cord. Such facilitation of nociceptive processing can exacerbate pain responses, lower pain threshold, and produce a persistent pain state (1-3). In contrast, stressful stimuli activate the hypothalamo-pituitary-adrenocortical axis (4) and release glucocorticoids, such as corticosterone (B); the ensuing activation of glucocorticoid receptors (GR) can reduce pain responses and increase pain threshold, a condition referred to as stress-induced analgesia (5, 6). Glucocorticoids can also reduce inflammation (7), and they are frequently used to treat painful inflammatory rheumatic diseases (8).
test the hypothesis that the formalin-induced increase in corticosterone reduces pain and inflammation, we next evaluated the effect of adrenalectomy (to prevent activation of glucocorticoid receptors) or high-dose dexamethasone (to saturate glucocorticoid receptors) on nociceptive processing in the formalin test. Neither adrenalectomy nor dexamethasone changed behavioral or cardiovascular nociceptive responses. Furthermore, the increases in blood pressure and heart rate produced by formalin may not be mediated by adrenomedullary catecholamine release. In addition, we conclude that the nociceptive component of the formalin stimulus is sufficient to activate the pituitary-adrenocortical system in the awake rat, but that the resulting release of corticosterone does not feed back and reduce nociceptive processing. (Endocrinology 139: [2407] [2408] [2409] [2410] [2411] [2412] [2413] 1998) T ISSUE injury and an accompanying inflammation are associated with persistent stimulation of primary afferent C-fibers, which transmit nociceptive messages from the periphery to the dorsal horn of the spinal cord. This process can be facilitated by both an injury-induced release of proinflammatory peptides from nerve terminals in the periphery and by a noxious stimulus-induced sensitization of dorsal horn neurons in the spinal cord. Such facilitation of nociceptive processing can exacerbate pain responses, lower pain threshold, and produce a persistent pain state (1) (2) (3) . In contrast, stressful stimuli activate the hypothalamo-pituitary-adrenocortical axis (4) and release glucocorticoids, such as corticosterone (B); the ensuing activation of glucocorticoid receptors (GR) can reduce pain responses and increase pain threshold, a condition referred to as stress-induced analgesia (5, 6) . Glucocorticoids can also reduce inflammation (7), and they are frequently used to treat painful inflammatory rheumatic diseases (8) .
Although there is considerable information regarding stress-induced activation of the pituitary-adrenal system, the contribution of pain-induced activation of this system to the control of nociception and inflammation remains unclear. Indeed, it is still not clear whether the nociceptive component of the formalin stimulus (independent of other components such as arousal, the stress associated with handling, and stimulation of high-threshold primary somatosensory afferents) is an adequate stimulus of the pituitary-adrenal system. Although many studies suggest that noxious stimuli activate the hypothalamo-pituitary-adrenocortical (HPA) axis, (9 -18), Bereiter and colleagues found that neither electrical stimulation of the tooth pulp nor thermal stimulation of the cornea increased the plasma concentration of ACTH (although they did show that the noxious stimuli potentiated the ACTH release produced by hemorrhage) (19, 20) . Because the use of general anesthetics in these studies may have eliminated a direct effect of noxious stimulation on the release of pituitary-adrenocortical hormones, we have directly tested the hypothesis that the nociceptive component of a painful stimulus is sufficient to activate the pituitary-adrenocortical system in the awake animal. To this end, we evaluated the effects of noxious stimulation (injection of formalin into the hindpaw) on pain-related behavior, plasma ACTH, and B in the awake rat. Unlike traditional reflex tests of nociception (e.g. tail-flick, hot-plate), pain produced by the hindpaw injection of formalin results from persistent tissue damage and, thus, more closely resembles clinical pain conditions (21) . Another im-portant feature of the formalin test is its biphasic nature; the first and second phases of the formalin response are thought to represent acute and persistent nociception, respectively (1, 2) . Both phases are readily quantifiable and are conserved across several measures, including pain-related behavior (22) , increases in arterial pressure (23) , and neuronal activity of primary afferent axons (24) and spinal cord neurons (25) . In the present study, we obtained multiple measurements of ACTH and B to evaluate pituitary-adrenocortical activity during both acute and persistent phases of the formalin response. Next, because B can reduce the inflammation that is frequently associated with peripheral hyperalgesia and pain (26, 27 ) via a negative feedback regulation, further studies evaluated the contribution of formalin-evoked increases in B to the magnitude of behavioral and cardiovascular responses.
Materials and Methods Animals
Male, Sprague-Dawley rats (260 -330 g) were obtained from Charles River Laboratories (Hollister, CA). Several days before surgery, the animals were housed individually in standard clear plastic cages in a temperature-controlled room (20 Ϯ 1 C) on a 12-h light, 12-h dark cycle (0600 h, lights on), with food and water provided ad libitum. The Institutional Animal Care and Use Committee of the University of California, San Francisco, approved all protocols.
Catheterization
To minimize pituitary-adrenocortical activation associated with handling, we used remote iv catheters to sample the plasma for ACTH and B and to measure blood pressure and heart rate. Venous jugular, carotid arterial, and femoral arterial catheters were constructed by heat-fusing a 4.2-, 3.2-, or 4.0-cm length of PE-10 polyethylene tubing (Becton Dickinson, Sparks, MD) to a 6.0-, 6.0-, or 17.5-cm length of PE-50 tubing, respectively. The catheters were inserted under pentobarbital anesthesia (50 -60 mg/kg). Vessels were isolated by blunt dissection, with care taken to avoid injury to the sciatic or vagus nerves. Through a small slit cut into the right jugular vein, the left carotid artery, or the femoral artery, a catheter (prefilled with 100 IU/ml heparin) was advanced proximally to the vena cava, aortic arch, or renal bifurcation of the abdominal aorta, respectively. After securing the catheter to the vessel with 4 -0 suture, the PE-50 end of the catheter was tunneled under the skin, exteriorized at the nape, and sutured to the dorsal neck muscles. After recovery from anesthesia, the animals were returned to their cages and allowed to recover for a minimum of 3 days before testing.
Adrenalectomy (ADX)
Bilateral (n ϭ 7) or sham ADX (n ϭ 9) was performed just before femoral arterial catheterization. To maintain normal plasma corticosterone levels until testing, and thus reduce the long-term effects of ADX [e.g. changes in neuropeptide content (28) ], adrenalectomized rats were supplied with corticosterone (25 g/ml) and 0.5% NaCl in their drinking water. This procedure permits the normal circadian rise in B that occurs during the dark cycle, when rats consume 70 -75% of their daily fluid intake (29) . The drinking water was removed on the morning of testing, at least 3 days after surgery. Testing began approximately 2 h after removal of the drinking water, sufficient time for B levels to decline to low and steady levels (30) .
Dexamethasone (DEX) pretreatment
At least 2 days after femoral arterial catheterization (the evening before formalin injection), rats were sc injected with either DEX (250 g/kg, n ϭ 12) or saline (n ϭ 12). A second injection of DEX (250 g/kg) or saline was administered 2 h before formalin injection.
Experimental protocol
Because adaptation to the test environment not only allows hormone levels to reach baseline, but also decreases the variability associated with behavioral measurement in the formalin test (21) , each animal was transferred to a bedded 10 ϫ 10 ϫ 10-inch Plexiglas box in the laboratory, with food and water (or 0.5% NaCl) provided ad libitum, at least 16 h before testing (ϳ1700 h). After this acclimation period, the arterial and/or venous catheters were connected, via PE-50 tubing, to a pressure transducer (Kobe, Arvada, CO) and/or an infusion pump (CMA/100, Carnegie-Mellon). Cardiovascular recording began at least 20 min later; this time period allows MAP and heart rate to return to a resting state after the sympathetic activation produced by handling (31) . Next, animals received a 50 l sc injection of either sterile saline or formalin (37%, wt/wt, formaldehyde, diluted in 0.9% saline) with a 30-gauge needle into the plantar surface of the right hindpaw (23) . Each animal was used only once, i.e. neither saline nor formalin injection was repeated in the same animal.
Recording of formalin response data
Both pain-related behavior and cardiovascular responses are reliable measures of the central transmission of nociceptive signals in the formalin test (21) . To quantify flinching and licking behavior during phase 1, the number of flinches or the number of seconds spent licking during the second and third minute after injection were counted as previously described (32) . From 8 -90 min, flinches and time spent licking were counted for 2 min at 5-min intervals. These numbers were divided by 2 to yield values per min. With this method, behavior in two animals was simultaneously recorded by one observer at 1-2, 2-3, and then 8 -10, 13-15 .. 88 -90 min after the formalin injection. To quantify cardiovascular responses, arterial pressure waveforms were first amplified and then conditioned by a digital blood pressure analyzer (Micromed, Inc., Louisville, KY) to yield mean arterial pressure (MAP) and heart rate. Data points were collected at 1-min intervals, each of which represents 5 seconds of processed information. Inflammation was assessed 90 min after the injection of formalin, by measuring paw thickness with a microcaliper (Mitsutoyo, Kanagawa, Japan), which is accurate to 0.01 mm.
Remote collection of blood
To obtain baseline measurement of ACTH and B after overnight acclimation to the test environment, 140-l samples of blood were remotely withdrawn, using a venous jugular or carotid arterial catheter, 15 and 5 min before the injection of saline (n ϭ 8) or 5.0% formalin (n ϭ 11). To estimate the stimulus-intensity dependence of the hormonal responses, we also evaluated the effects of 1.25% in four animals. To determine the temporal profile of formalin-evoked changes in hormone levels, additional 140-l samples were taken at 2, 10, 15, 30, 45, 60, and 75 min after formalin injection. After each sample was collected, the volume was replaced with saline.
Analysis of ACTH and B
Samples were centrifuged, and the plasma was collected and frozen at Ϫ80 C. After thawing, ACTH was determined by RIA (33) , with antiserum R7 generously provided by Dr. W. Engeland. The antiserum is used on unextracted plasma (5-50 ul) at a working dilution of 1:165,000. The assay incorporates the use of late trace addition of 125 I (Incstar, Stillwater, MN), second antibody separation (1:10 goat antirabbit globulin; Antibodies, Inc., Davis, CA), and a buffer wash immediately before centrifugation. The ACTH assay is linear between 2.2-22.0 pg/tube, with inter-and intraassay coefficients of variation of 4.7% and 8.4%, respectively.
B was determined by RIA (34) or with an RIA kit (ICN Pharmaceuticals, Costa Mesa, CA) used at half-volume. These assays yield similar standard curves [ED 80 ϭ 65; ED 50 ϭ 311; and ED 20 ϭ 1554 ng/tube (35) ].
In the first case, B antiserum (Endocrine Sciences B3-163) was used with 125 I-corticosterone (ICN Pharmaceuticals). The B assay is linear between 0.065-1.44 ng/tube, with inter-and intraassay coefficients of variation of 6.9% and 7.1%, respectively.
Data analysis and statistics
After the animals had acclimated to the test environment, five sequential steady-state baseline cardiovascular values were recorded. The average of these baseline values was then subtracted from each poststimulus value, to yield changes in MAP or heart rate at each of the timepoints after the formalin injection. Formalin-evoked flinching, cardiovascular, and hormonal responses were analyzed by two-way repeated-measures ANOVA, with Group as the between-subjects variable and Time as the repeated measure. Behavioral and cardiovascular responses during phase 1 (min 1-5), interphase (min 11-15), and phase 2 (min 20 -60) were separately evaluated. When significant, these analyses were followed by post hoc t-tests. Baseline (preformalin) cardiovascular and hormonal values were compared between groups with unpaired, independent t tests.
Materials
Stock solutions of formalin (aqueous solution of 37%, wt/wt, formaldehyde; Fisher, Fair Lawn, NJ) were freshly diluted in 0.9% isotonic sterile saline (Baxter Healthcare Corp., Deerfield, IL). Pentobarbital was obtained from Abbott Laboratories (North Chicago, IL). DEX sodium phosphate was obtained from American Reagant Labs (Shirley, NY).
Results

Formalin-evoked increases in plasma ACTH and corticosterone (B)
To determine the effects of persistent noxious stimulation on the pituitary-adrenocortical system, we quantified ACTH and corticosterone in the plasma before and after an sc injection of saline or formalin into the intraplantar surface of the right hindpaw.
As illustrated in Fig. 1A , sc injection of dilute formalin into the hindpaw evokes an early-onset behavioral response [termed: phase 1 (22) ] that lasts approximately 5 min and, after a brief quiescent interphase, a second prolonged behavioral response (termed: phase 2) that lasts approximately 50 min. Injection of saline into the hindpaw did not produce flinching or licking behavior. As illustrated in Fig. 1B , however, saline injection produced a peak increase in ACTH (to 113 Ϯ 18 pg/ml) at 2 min, which gradually returned to baseline values. In contrast, 5% formalin produced significantly greater increases in ACTH [F(1, 25) ϭ 11.3, P Ͻ 0.005], with significant post hoc differences at 2, 30, 45, and 60 min (P Ͻ 0.01). Fig. 1C also illustrates that saline injection produced a peak increase in B (to 12.1 Ϯ 3.5 g/dl), at 15 min, that gradually returned to baseline values. In contrast, 5% formalin produced significantly greater and longer duration increases in B [F(1, 17) ϭ 5.7, P Ͻ 0.05], with significant post hoc differences at 30, 45, and 60 min (P Ͻ 0.05).
Relationship between stimulus intensity and response magnitude
To determine the relationship between stimulus intensity and formalin-evoked responses, we next compared the stimulus-response profiles of evoked changes in hormone levels, behavior, and inflammation. Table 1 shows that all of the groups displayed mean baseline values of ACTH and B that were below 100 pg/ml and 2.0 g/dl, respectively. These values indicate that the groups experienced minimal stress before the injection.
As illustrated in Fig. 2 , both concentrations of formalin produced greater responses in all measures, compared with baseline values or saline injection. Fig. 2, A and B, also illustrate that the average magnitude of ACTH and B responses did not increase as stimulus intensity was raised from 1.25% to 5.0% formalin. In contrast, Fig. 2 , C and E, illustrate that the magnitude of flinching, licking, and inflammatory responses increased with formalin concentration (P Ͻ 0.05).
ADX ϩ supplementation of B in the drinking solution
Because B can reduce the inflammation that is frequently associated with peripheral hyperalgesia and pain (26, 27 ) via a negative feedback regulation, the next study evaluated the contribution of formalin-evoked increases in B to the magnitude of behavioral and cardiovascular responses. Because 1.25% formalin often produces weak and variable behavioral and/or cardiovascular responses, we slightly increased the concentration of formalin to 2.0%. We have previously shown that this concentration produces moderate, yet reliable, nociceptive responses (23, 36) that can be either increased or decreased, depending on the experimental treatment (23, 37) . Table 1 shows that thymus weight of the Sham and ADX ϩ B-water groups did not differ, indicating that the latter group was eucorticoid and that corticosteroid replacement was successful. As illustrated in Fig. 3 , ADX ϩ B did not significantly change flinching behavior, licking behavior, MAP responses, or heart rate responses during phase 1 or phase 2 (P Ͼ 0.05). Table 1 also shows that ADX ϩ B did not significantly change formalin-evoked inflammation.
High-dose DEX treatment
To further test the relationship between GR stimulation and nociception in the formalin test, we also evaluated the effects of DEX or saline vehicle. To produce robust nociceptive responses associated with a strong inflammatory response, we used a relatively high concentration of formalin (5.0%). Table 1 shows that DEX pretreatment decreased thymus and adrenal weights. This indicates that the DEX group was hypercorticoid (38) . Table 1 also shows that DEX decreased the inflammation (paw thickness) associated with formalin injection (P Ͻ 0.05). As illustrated in Fig. 4 , DEX did not change flinching or licking behavior or MAP responses (P Ͼ 0.05). Surprisingly, DEX increased the magnitude of formalin-evoked heart rate responses during phase 2 [F(1, 13) ϭ 5.3, P Ͻ 0.05]; however, the fact that DEX also reduced baseline heart rate (Table 1) shows that absolute heart rate (but not change in heart rate) during formalin testing was not different between the saline and DEX groups.
Discussion
Nociceptive input activates the pituitaryadrenocortical system
Numerous studies have shown that short periods of handling or restraint activate the pituitary-adrenocortical system, as measured by increases in the plasma concentrations of ACTH and B (17, 39) . Because the handling associated with saline injection increased ACTH and B, we conclude that the injection procedure required to perform the formalin test significantly activates the pituitary-adrenocortical system. Thus, to test the hypothesis that the nociceptive component of the formalin stimulus, independent of other components (such as arousal and the stress associated with handling) is a ADX rats were given B in their drinking water (25 g/ml) until tested for nociceptive responses to 2.0% formalin (50 l, intraplantar). DEX was administered twice sc (250 g/kg), 16 and 2 h preinjection, and then tested for nociceptive responses to 5.0% formalin (50 l, intraplantar) . n, number of animals; N/A, not available.
a Significantly (P Ͻ 0.05) different from the control group.
FIG. 2.
Average change per sampling period before hindpaw injection (baseline) or 20 -60 min after hindpaw injection (i.e. during phase 2) in plasma ACTH, plasma corticosterone, flinching behavior, licking behavior, and paw thickness, after the injection of saline (n ϭ 8), 1.25% formalin (n ϭ 4), and 5.0% (n ϭ 11) formalin. The thickness changes represent the difference in thickness between the injected and control paws. *, P Ͻ 0.05, 1.25% vs. 5.0% formalin.
sufficient to activate the pituitary-adrenocortical system in the awake rat, it was critical to demonstrate that formalin produces greater increases in hormone levels than does restraint and saline. Consistent with this hypothesis, formalin produced greater and longer-lasting increases in ACTH and B, particularly during the latter part of phase 2, when the ACTH and B responses to handling were largely over. These results indicate that formalin-evoked increases in ACTH and B during the latter part of phase 2 reflect nociceptive input, rather than the stress associated with handling. Our study is the first to evaluate plasma ACTH and B, during both acute and persistent nociception, in a widely accepted model of inflammatory pain, the formalin test. Although other studies have shown that formalin increases the plasma concentration of ACTH (16 -18) , formalin was injected at unusual concentrations (i.e. 10%) (16) or at unusual sites [such as the ip space (18) , or the thigh (17)], and ACTH measurements were not ascertained before 30 min (i.e. during the first phase of the formalin response) (16 -18) . Surprisingly, Aloisi et al. (16) reported that the intraplantar injection of 10% formalin did not change the plasma concentration of B. Because control levels of B were much lower in our study (Ͻ2.0 ug/dl) than in the report of Aloisi et al. (16) (Ͼ7.0 ug/dl), we believe that a marked increase in baseline adrenocortical activity in the latter study may have contributed to this difference. Based on our results and on clinical studies showing that plasma levels of ACTH and cortisol are elevated during the pain associated with surgery (10 -13), trigeminal neuralgia (14) , or cluster headache (15), we conclude that nociceptive input activates the pituitaryadrenocortical system.
In light of our results, it is a conundrum that Bereiter and colleagues (19, 20) found that neither electrical stimulation of the tooth pulp nor thermal stimulation of the cornea increased the plasma concentration of ACTH. The discrepancy between these results and ours may be related to the different types of noxious stimuli used and to the use of general anesthesia in the Bereiter study. In fact, because general anesthetics not only decrease the transmission of nociceptive signals (23) , but also may alter the release of ACTH and corticosterone after stimulation with insulin (40) or ether (41) , it is possible that anesthesia reduces noxious stimulusevoked changes in pituitary-adrenocortical activity.
At least two physiological mechanisms could underlie the increase in plasma ACTH and B after intraplantar formalin injection. First, similar to an adjuvant-induced arthritis model of chronic inflammation (9, 42), Aloisi et al. (16) found that formalin increased the blood-borne release of interleukin-6. In addition to other cytokines (such as interleukin-1), interleukin-6 is capable of increasing ACTH and corticosterone via several mechanisms. For example, cytokines can directly stimulate hypothalamic corticotropin-releasing factor release from neuronal cell bodies in the paraventricular nucleus of the hypothalamus or from terminals in the median eminence into the hypophysial-portal circulation (42, 43) . Second, the formalin stimulus robustly activates ascending pain pathways, which may, in turn, activate the HPA axis. For example, at the level of the primary afferent fiber, interruption of nociceptive transmission with neonatal capsaicin treatment (which destroys most C-fibers) decreases the ability of ip formalin (18) , or the intraplantar injection of the inflammatory agent, complete Freund's adjuvant (4), to increase ACTH. Also, interruption of nociceptive transmission at the spinal level decreases the ACTH response to noxious stimuli in dogs and humans (10, 12, 13) . These studies indicate that both the behavioral and pituitary-adrenal responses may be mediated by formalin-induced activation of primary afferent C-fibers and ascending nociceptive spinal cord neurons. Because many of the above studies were performed in the anesthetized subject, however, future experiments should address the mechanisms by which noxious stimuli stimulate the HPA axis in the awake subject.
The present results suggest that the behavioral and pituitary-adrenal systems differ in their sensitivity to formalin concentration. We found that the maximal stimulus intensity for the behavioral/inflammatory responses was at least 5.0% formalin, whereas that of the pituitary-adrenal response was only 1.25%. Because other types of stressors, such as restraint, produce much larger plasma levels of ACTH (39) and B (17, 39, 44) than were found in the current study, the formalin effect is certainly submaximal. We speculate that a ceiling effect precludes the ability of higher formalin concentrations to evoke maximal pituitary-adrenal responses.
Adrenal activity does not mediate or modulate nociception in the formalin test
Although B exerts antiinflammatory actions (45) , and there is evidence that inflammation contributes to nociception in the formalin test (21) , the present studies indicate that the formalin-evoked release of endogenous corticosterone is not antinociceptive. First, prevention of acute corticosteroid responses by ADX did not significantly increase the flinching, licking, or MAP responses evoked by formalin. Second, despite our demonstration that DEX acted on GRs to decrease thymus and adrenal weight and formalin-evoked inflammation, this treatment did not inhibit the flinching, licking, MAP, or heart rate responses. Although some studies found that DEX decreases formalin-evoked behavior, this effect only occurred at very high (6 -30 mg/kg) doses (46, 47).
Third, in preliminary studies, we have provided evidence that chronic stress (exposure to 4 C for 4 h/day for 7 days), which produces a central facilitation of the HPA axis (i.e. exaggerated stimulus-evoked increases in corticosterone), does not decrease flinching, licking, MAP, or heart rate responses after formalin injection (48) . We conclude that formalin-evoked release of corticosterone does not feed back and reduce nociception.
Consistent with our results, lesions of the paraventricular nucleus of the hypothalamus, a key input to the pituitary, did not alter pain-related behavior during phase 2 of the formalin test (49, 50) . However, because glucocorticoids seem to modulate bradykinin-associated inflammation (4, 51), neuropeptide content in doral root ganglia (28, 52) and noxious stimulus-evoked expression of c-fos within the spinal trigeminal nucleus, it remains possible that glucocorticoids contribute to the magnitude of nociceptive responses in models of pain other than the formalin test. Furthermore, even though glucocorticoids do not seem to modulate nociceptive processing in response to a single noxious stimulus (such as the injection of formalin), it is still possible that glucocorticoids regulate nociception in longer-duration models of chronic pain.
The present studies indicate that the formalin-induced increase in blood pressure and heart rate are not mediated by adrenomedullary catecholamine release. Consistent with this result, Casto et al. (53) found that ADX did not prevent a nonnoxious airpuff stimulus from evoking increases in blood pressure and heart rate. Further studies are needed to evaluate the spinal and supraspinal sites that contribute to the cardiovascular responses induced by noxious stimuli in awake animals.
In summary, the nociceptive component of intraplantar formalin injection activates the pituitary-adrenocortical system in the awake, freely-moving rat. However, the ensuing release of corticosterone does not feed back and reduce nociceptive processing.
